Floatz logo

Cetuximab

Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity cohort.

Asset / SponsorPhaseRating
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Carboplatin
Rapa Therapeutics LLC
Phase 1/2B
Abiraterone Acetate
MacroGenics
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Enzalutamide
MacroGenics
Phase 2CCC

View all 22 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →